drugset / Trial / NCT06656442

"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"

NCT06656442

Phase 3 Completed 60 enrolled Ain Shams University
RandomizedParallel-groupSingle-blindTreatment

Summary

The investigators need to test the effect of Trimetazidine on the pro-inflammatory marker Interleukin - 18 , NIHSS score, and mRs score of acute ischemic stroke patients.

Timeline

Start
2024-09-01
Primary completion
2025-02-28
Completion
2025-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trimetazidine Small molecule 35 mg

Indications